36 related articles for article (PubMed ID: 19665377)
1. Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model.
Facchin C; Fraga-Timiraos AB; Schmitt J; Babaa N; Pannu N; Aliaga A; Larroque AL; Jean-Claude BJ
Cells; 2023 Mar; 12(6):. PubMed ID: 36980255
[No Abstract] [Full Text] [Related]
2. Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent.
Golabi N; Larroque AL; Peyrard L; Williams C; Jean-Claude BJ
Invest New Drugs; 2021 Feb; 39(1):240-250. PubMed ID: 32648119
[TBL] [Abstract][Full Text] [Related]
3. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives.
Asif M
Int J Med Chem; 2014; 2014():395637. PubMed ID: 25692041
[TBL] [Abstract][Full Text] [Related]
4. ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Ait-Tihyaty M; Rachid Z; Larroque-Lombard AL; Jean-Claude BJ
Invest New Drugs; 2013 Dec; 31(6):1409-23. PubMed ID: 23959266
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.
MacPhee M; Rachid Z; Todorova M; Qiu Q; Belinsky G; Jean-Claude BJ
Invest New Drugs; 2011 Oct; 29(5):833-45. PubMed ID: 20428924
[TBL] [Abstract][Full Text] [Related]
6. [Advances in research on treatment of breast cancer with lapatinib].
Ma CD; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
[No Abstract] [Full Text] [Related]
7. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
[TBL] [Abstract][Full Text] [Related]
8. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
[TBL] [Abstract][Full Text] [Related]
9. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
Rachid Z; Macphee M; Williams C; Todorova M; Jean-Claude BJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5505-9. PubMed ID: 19665377
[TBL] [Abstract][Full Text] [Related]
13. The development of HKI-272 and related compounds for the treatment of cancer.
Wissner A; Mansour TS
Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]